Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma	gastroesophageal adenocarcinoma	Recruiting	Phase 2	2026-08-11		NCT06043427

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Canadian Cancer Trials Group	73
Jazz Pharmaceuticals	60

18 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Allan Blair Cancer Centre	Regina	Canada	76
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Canada	45
BCCA - Vancouver	Vancouver	Canada	22
CancerCare Manitoba	Winnipeg	Canada	98
Centre Integre Universitaire De Sante Et De Services	Montreal	Canada	1
CHUM-Centre Hospitalier de l'Universite de Montreal	Montreal	Canada	20
Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Canada	60
Kingston Health Sciences Centre	Kingston	Canada	91
Lakeridge Health Oshawa	Oshawa	Canada	18
London Health Sciences Centre Research Inc.	London	Canada	13
Odette Cancer Centre	Toronto	Canada	20
Ottawa Hospital Research Institute	Ottawa	Canada	46
QEII Health Sciences Centre	Halifax	Canada	11
Royal Victoria Regional Health Centre	Barrie	Canada	35
Saskatoon Cancer Centre	Saskatoon	Canada	75
St. Michael's Hospital	Toronto	Canada	62
University Health Network	Toronto	Canada	52
Waterloo Regional Health Network (WRHN)	Kitchener	Canada	6